Journal History
| 2013 | The inaugural issue was released. Biomedicines was published as a quarterly journal. |
| 2015 | Biomedicines established the following section:
|
| 2016 | Biomedicines was indexed in Emerging Sources Citation Index (ESCI) of the Web of Science. Biomedicines established the following section:
|
| 2017 | Biomedicines was indexed in PubMed and Scopus. Biomedicines starts the Travel Awards project. |
| 2018 | Biomedicines established the following section:
|
| 2019 | Biomedicines was indexed in Science Citation Index Expanded (SCIE). Biomedicines established the following sections:
- Nanotechnology and Biotechnology was renamed as Biomedical Materials and Nanomedicine; - Therapeutic Strategies in Different Diseases was renamed as Molecular and Translational Medicine; - Thrombosis and Hemostasis was discontinued; - Model Systems in Research and Development was discontinued; - Virology, Vaccines and Viral Vectors was discontinued; - Tumor Cell Biology was discontinued. |
| 2020 | Biomedicines adopted a monthly publication schedule. Biomedicines received its 2019 Impact Factor (4.717), ranked 36/270 (Q1) in “Pharmacology & Pharmacy”, and ranked 30/138 (Q1) in “Medicine, Research & Experimental”. Biomedicines published its 1,000th paper. Biomedicines rearranges the following sections:
|
| 2021 | Biomedicines starts the Young Investigator Award project. Biomedicines organized the 1st International Electronic Conference on Biomedicine (ECB 2021). Biomedicines organized the First Canadian Peptide and Protein Community Virtual Symposium (CPPC 2021). Biomedicines received its 2020 Impact Factor (6.081), ranked 32/275 (Q1) in “Pharmacology & Pharmacy”, ranked 32/140 (Q1) in “Medicine, Research & Experimental”, and ranked 65/298 (Q1) in “Biochemistry & Molecular Biology”. Biomedicines rearranges the following sections:
|
| 2022 | The year 2022 marks the 10th Anniversary of Biomedicines. Biomedicines announced the 2022 Best Paper Award for Anniversary Special Issues/2022 Early-Career Women Award/2022 Young Investigator Award. Biomedicines received its 2021 Impact Factor (4.757), ranked 87/279 (Q2) in “Pharmacology & Pharmacy”, ranked 62/139 (Q2) in “Medicine, Research & Experimental”, and ranked 121/297 (Q2) in “Biochemistry & Molecular Biology”. |
| 2023 | Biomedicines received its 2022 Impact Factor (4.7), ranked 69/277 (Q1) in “Pharmacology & Pharmacy”, ranked 54/136 (Q2) in “Medicine, Research & Experimental”, and ranked 92/285 (Q2) in “Biochemistry & Molecular Biology”. Biomedicines announced the 2024 Travel Award/2022 Best Paper Award/2023 Outstanding Reviewer Award/2023 Young Investigator Award. |
Editor-in-Chief
| 2013–2016 | Editor-in-Chief: Prof. Dr. Kenneth Cornetta |
| 2016–present | Editor-in-Chief: Prof. Dr. Shaker A. Mousa |
Section Editor-in-Chief
| 2016–2022 | Section Editor-in-Chief: Dr. Vincenzo Cerullo for the Section on Tumor Immunology and Immunotherapy |
| 2016–present | Section Editor-in-Chief: Dr. Bruno Meloni for the Section on Neurologic Disease |
| 2019–present | Section Editor-in-Chief: Prof. Dr. Jun Lu for the Section on Drug Discovery and Development Section Editor-in-Chief: Dr. Veronique Baud for the Section on Cancer Therapeutics |
| 2022–present |
Section Editor-in-Chief: Prof. Dr. Paul Rösch for the Section on Cell Biology and Pathology |
